Washington, D.C.—The U.S. Senate Agriculture Appropriations Committee failed to include legislation passed by the House of Representatives that would appropriate $100,000 for FDA to perform an evaluation and set a safe level of CBD for consumers to use each day, according to a press release from the Natural Products Association (NPA).
The Committee only included language instructing FDA to report back to them in 90 days.
Related: NPA Tells Congress: Regulate CBD, or Vaping Crisis Will Repeat
FTC Warns More CBD Companies Over Health Claims
NPA Submits Comments to FDA on NDIs and CBD
“What we saw today was the U.S. Senate Agriculture Committee Fail to include any meaningful legislative language that would force FDA to do its job when it comes to CBD,” said Daniel Fabricant, Ph.D., president and CEO of NPA. “Sadly, this approach will lead to nothing but problems. This should have been an easy choice for the committee; they should have taken their lead from the U.S. House of Representatives where Congressman McNerney had already had an amendment pass that would actually protect American consumers. However, the fight is not over. We are continuing our work to ensure that the one in seven Americans that use a CBD product every day have the ability to believe that the FDA is doing its job and not taking the path of least resistance. We encourage everyone to tell their Congressman and Senators to set a safe level of daily consumption for CBD.”